TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27100415
Drug: PUD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUD with proton-pump inhibitors (PPIs) use
Study: 22007026
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (LDL-C target < 130 mg/dL)
Study: 22007026
Drug: Multifactorial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial treatment
Study: 20868531
Drug: Multifactorial adherence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial adherence-based intervention (motivational interviews, pill reminders, family support, blood pressure self-recording, simplification of dosing regimen)
Study: 18604566
Drug: Multimodal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal group therapy program (20 treatment days over 10 weeks)
Study: 15796645
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with contingency management (CM) for 12 weeks
Study: 10522578
Drug: mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine 1% with 1 ml saline
Study: 10522578
Drug: mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine 1% with 5 ml saline
Study: 10522578
Drug: mepivacaine 1.5%
Normalized name: mepivacaine 1.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepivacaine 1.5% with 10 ml saline
Study: 7009594
Drug: Weekly coated‐charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly coated‐charcoal hemoperfusion (CCHP)
Study: 23429100
Drug: N-MUF (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-MUF (3000 ml)
Study: 19075045
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg) with acidic beverage
Study: 19075045
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg) with higher gastric pH
Study: 19075045
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg) plus nutritional supplement (Boost)
Study: 19075045
Drug: Posaconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (200 mg) plus nutritional supplement (Boost)
Study: 19075045
Drug: Posaconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (400 mg) during high-fat meal
Study: 17488963
Drug: Intensive anti-ischemic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive anti-ischemic drug therapy
Study: 23146135
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment for 6 months
Study: 25470087
Drug: Aripiprazole long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole long-acting injection (LAI)
Study: 23872254
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng extract (RGE) 1500 mg orally three times a day for 7 days
Study: 18759293
Drug: Ocrelizumab (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocrelizumab (doses of 200 mg and higher) plus MTX
Study: 18759293
Drug: Ocrelizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocrelizumab (10 mg and 50 mg)
Study: 10757543
Drug: Diet rich
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet rich in alpha-linolenic acid (8.3 g/d)
Study: 8922306
Drug: N-acetylcysteine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine supplementation (600 mg daily for 3-9 months)
Study: 4002807
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg indapamide once daily
Study: 29385054
Drug: High d‐allulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: High d‐allulose (7 g × 2 times/day)
Study: 19713253
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (oral antivirals and analgesics)
Study: 14650210
Drug: mexidol, intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexidol, intravenously instilled in a daily dose of 2‐4 mg/kg over a period of 10 days in combination with a standard neurometabolic scheme
Study: 4061344
Drug: No Se
Normalized name: ZINC OXIDE 11.12 g in 50 mL TOPICAL CREAM [UV defense me. No sebum sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Se supplements (control)
Study: 31050933
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser (DL) as an adjunct to Kirkland flap surgery
Study: 29179625
Drug: Pediatric malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric malaria vaccine trial (GSK/PATH‐MVI RTS,S)
Study: 25243680
Drug: STOPP/START medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOPP/START medication intervention
Study: 26861468
Drug: Usual pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Usual pharmaceutical care
Study: 20108006
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg
Study: 22526437
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lidocaine 20 mg and nitroglycerin 0.1 μg/kg
Study: 17610056
Drug: Levosimendan (24‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (24‐h infusion of 0.1 mug/kg/min)
Study: 8194616
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC), 100 mg from days 2 to 6
Study: 8194616
Drug: Natural cycle
Normalized name: Natural Cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural cycle (no treatment)
Study: 2048868
Drug: Norfloxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 400 mg orally every 12 hours
Study: 27771572
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsule
Study: 12087344
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (single dose 900 mg)
Study: 12087344
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (long-term treatment 300 mg 3 times a day)
Study: 2612091
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin A (CyA)
Study: 23352604
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus FOLFIRI (5-fluorouracil 400mg/m² on day 1 plus 2,400 mg/m² as a 46-h infusion, leucovorin 400mg/m² on day 1, and irinotecan 180 mg/m² on day 1)
Study: 21205360
Drug: Milk supplementation
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplementation (1000 mg Ca/d)
Study: 11403365
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum cholesterol (> 6.8 mmol/l)
Study: 11403365
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum creatinine (> 155 micromol/l)
Study: 29855972
Drug: LY2963016 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2963016 insulin glargine (LY IGlar)
Study: 24043733
Drug: Daily manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily manual lymphatic drainage and bandaging followed by compression garments
Study: 11405809
Drug: Almotriptan malate,
Normalized name: Almotriptan Malate, 6.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan malate, 12.5 mg
Study: 11405809
Drug: Sumatriptan succinate,
Normalized name: SUMAtriptan Succinate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan succinate, 50 mg
Study: 24479576
Drug: Narrative Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Therapy (NT)
Study: 23389497
Drug: 3 additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 additional doses of L-asparaginase (6000 IU/m2/dose) during consolidation treatment (3A arm)
Study: 23389497
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without additional doses of L-asparaginase (0A arm)
Study: 19892856
Drug: Placebo (detuned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (detuned ultrasound therapy and detuned short‐wave therapy)
Study: 15328092
Drug: Amoxicillin-clavulanate 2,000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 2,000/125 mg
Study: 11446908
Drug: Amoxicillin-clavulanate 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate 875/125 mg
Study: 10780133
Drug: No supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supportive agent
Study: 3119288
Drug: Levonorgestrel and
Normalized name: levonorgestrel and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel and Ethinylestradiol in tablet form (150/30)
Study: 3119288
Drug: Levonorgestrel and
Normalized name: levonorgestrel and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel and Ethinylestradiol in capsule form
Study: 14982548
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus CM with an expected maximum of $240 of reinforcement
Study: 11709606
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy including sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7.5 mg/week), and prednisolone (initially 60 mg/day, tapered to 7.5 mg/day)
Study: 3367455
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 400 mg five times daily
Study: 22005905
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of 0.5% hyperbaric bupivacaine (Group I)
Study: 12624696
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron orally
Study: 3550340
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (bleomycin, Cytoxan, methotrexate, and 5-fluorouracil) in two cycles (one cycle if no tumor response) followed by standard treatment (combined irradiation and surgery or primary irradiation alone)
Study: 3550340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without prior chemotherapy)
Study: 16942534
Drug: Vardenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (20 mg)
Study: 8277478
Drug: Treatment failures
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failures
Study: 18854540
Drug: Episodic amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic amiodarone treatment
Study: 16227760
Drug: Irbesartan/HCTZ treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ treatment regimen
Study: 2286465
Drug: Co-trimoxazole (1.92
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (1.92 g)
Study: 29412363
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hour prior to bleaching
Study: 25091062
Drug: Antimicrobial susceptibility-guided
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial susceptibility-guided therapy
Study: 12565715
Drug: Warfarin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (2 mg per day)
Study: 16551898
Drug: Nalbuphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.1 mg/kg)
Study: 31353988
Drug: Rational-emotive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive behaviour therapy
Study: 28329434
Drug: COPE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE treatment (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)
Study: 20601736
Drug: Caffeine (CAF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF; 3.7 mg/kg BM)
Study: 20601736
Drug: Carbohydrate (CON;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CON; 1.8 g/kg BM)
Study: 16637728
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐pop
Study: 14509861
Drug: Cognitive‐behavioural stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural stress management/expressive supportive therapy (CBSM+) intervention
Study: 11002624
Drug: subsyde-CR (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: subsyde-CR (diclofenac in controlled release formulation using DRCM technology)
Study: 11002624
Drug: meloxicam (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam (standard formulation)
Study: 1430680
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) treatment
Study: 26633836
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg bid for seven days
Study: 18034990
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol for sedation
Study: 16130506
Drug: Oral disodium
Normalized name: etidronate disodium Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disodium pamidronate combined with calcium salts and vitamin D3 supplements
Study: 12193919
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (dilatation and curettage)
Study: 6344896
Drug: Conventional diuretics
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuretics
Study: 20814410
Drug: DAG oil
Normalized name: Daglutril
DrugBank: Daglutril (DB05796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Study: 20814410
Drug: TAG oil
Normalized name: ProVent SKIN TAG OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Study: 11748390
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg spinal ropivacaine
Study: 11748390
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg spinal ropivacaine
Study: 11748390
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg spinal ropivacaine
Study: 31549623
Drug: Test (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test (generic formulation)
Study: 31549623
Drug: Reference (branded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (branded formulation)
Study: 25422824
Drug: 6.6‐mm long
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.6‐mm long implants
Study: 30515480
Drug: 9.6‐mm or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.6‐mm or longer implants (augmented group)
Study: 20026256
Drug: Nanosomal Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanosomal Tacrolimus (5 mg/kg in rats, 10 mg/kg in mice)
Study: 1673645
Drug: Esmolol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 100 mg
Study: 1673645
Drug: Esmolol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 200 mg
Study: 7337792
Drug: Study treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment assigned to private physicians (specific treatment details not available)
Study: 28233012
Drug: Supervised structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised structured exercise programme (aerobic and resistance exercises performed bi-weekly, plus at least 30 min of brisk daily walks)
Study: 23955552
Drug: Intermittent tri-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent tri-weekly docetaxel (75 mg m(‐2) once tri-weekly) plus bicalutamide (50 mg once daily)
Study: 19815876
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) at 2 mg/kg
Study: 19815876
Drug: Artesunate (AS)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate (AS) at 4 mg/kg
Study: 28044135
Drug: ECVVH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECVVH treatment for 72 hours
Study: 28044135
Drug: Standard therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapies without ECVVH
Study: 18551200
Drug: Fluticasone 250
Normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 250 microg/salmeterol 50 microg plus montelukast 10 mg (F/S + M)
Study: 7352522
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration
Study: 8942325
Drug: Paracetamol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1.5 g
Study: 8942325
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paracetamol 1.5 g and diclofenac 100 mg
Study: 29444699
Drug: Intracervically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervically administered terlipressin
Study: 27510521
Drug: Voriconazole 400
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily thereafter
Study: 27510521
Drug: Posaconazole 400
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 400 mg twice daily
Study: 15049152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lycopene (Tomatol) per day during 24 weeks
Study: 9814452
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3-1000 mg/day in two divided doses)
Study: 21593118
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 750 mg dose of metyrapone
Study: 19331224
Drug: 10,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 IU epoetin-alpha thrice weekly
Study: 16504956
Drug: 15% sage
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% sage spray (140 microl sage extract per dose)
Study: 10904284
Drug: Enalapril (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (35 mg/day)
Study: 10904284
Drug: Losartan (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (175 mg/day)
Study: 10904284
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + Losartan (15 mg + 100 mg/day)
Study: 9060552
Drug: prednimustine 200
Normalized name: prednimustine
DrugBank: Prednimustine (DB12832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednimustine 200 mg/m2/d for 5 days per month for 18 months
Study: 27959713
Drug: Low-dose rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months
Study: 27959713
Drug: Very-low-dose rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months
Study: 27959713
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with a dose-adjusted vitamin K antagonist plus DAPT for 1, 6, or 12 months
Study: 20600481
Drug: Intradermal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal delivery using BD microneedle technology at 1/4 the IM antigen dose
Study: 8443746
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy after liver metastasis resection
Study: 19884008
Drug: Metronomic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronomic administration of pegylated liposomal-doxorubicin (PLD) at a dosage of 20mg/m² i.v. every two weeks
Study: 19082804
Drug: Cobamamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobamamide (2 tablets) orally and Psoralea tincture externally thrice a day for 3 months (Control group)
Study: 19082804
Drug: Zengse Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zengse Pill (ZSP)
Study: 14514497
Drug: Antidepressants (nortriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (nortriptyline or fluoxetine)
Study: 10772083
Drug: 3-drug arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-drug arm (rifabutin 600 mg daily, ethambutol 15 mg/kg daily, clarithromycin 1000 mg twice daily)
Study: 10772083
Drug: 4-drug arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-drug arm (rifampin 600 mg, ethambutol 15 mg/kg daily, clofazimine 100 mg daily, ciprofloxacin 750 mg twice daily)
Study: 25415292
Drug: 3-drug arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-drug arm
Study: 22727709
Drug: Duloxetine (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60-120 mg/d)
Study: 20465434
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil enriched with n-3 PUFA (6.5 ml daily for 12 months)
Study: 17650833
Drug: Ciclesonide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide, 200 microg once daily
Study: 12140346
Drug: Monthly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly telephone monitoring of psychological distress and home nursing visits
Study: 7755223
Drug: Recombinant glycoprotein
Normalized name: Recombinant glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant glycoprotein vaccine (gD2 and gB2 with MF59 adjuvant) administered intramuscularly at 0, 1, and 6 months
Study: 25175495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC + 0 mg MPH